BioInsights - Market access: evolving commercialization trends and strategies - spotlight

CELL & GENE THERAPY INSIGHTS

Market access: evolving commercialization trends and strategies

Neil Palmer

Guest Editor:

Neil Palmer, President and Principal Consultant at PDCI Market Access

August 2020

Download full spotlight

The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases

F Ali

23 September 2020

Commentary

Read more
Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies

N Palmer

3 September 2020

Foreword

Read more
Joint collaborations and future perspectives for gene therapies.

M Dabbous,

B Borissov,

C Dussart et al.

3 September 2020

Commentary

Read more
How should health technology assessment of ATMPs evolve in Europe?

M Toumi

2 September 2020

Interview

Read more
From rare monogenic diseases to Parkinson’s: market access considerations for gene therapy across large and small indications

P Meswani

28 August 2020

Interview

Read more
Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe

C Hague,

M Price

28 August 2020

Expert Insight

Read more
HTA evolution in Canada: considerations for cell and gene therapy

S McGurn

26 August 2020

Interview

Read more
Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

S Scheding,

H Main,

P Blomberg

18 August 2020

Commentary

Read more
Challenges in the adoption of regenerative medicine therapies, meeting summary

M Chaddah,

S McMahon,

J Kusena et al.

13 August 2020

Commentary

Read more
Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector

J Lambert

10 August 2020

Commentary

Read more